| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| R Fahlbusch, J Honegger, M Buchfelde. Acromegaly--the place of the neurosurgeon. Metabolism: clinical and experimental. vol 45. issue 8 Suppl 1. 1996-12-10. PMID:8769386. |
over 12 years, we performed 498 operations for growth hormone (gh)-secreting pituitary adenomas (489 in acromegaly and nine for gigantism), with 479 by the trans-sphenoidal and 19 by the transcranial route. |
1996-12-10 |
2023-08-12 |
Not clear |
| G Toli. The role of somatostatin agonistic analogs in the treatment of acromegaly. Metabolism: clinical and experimental. vol 45. issue 8 Suppl 1. 1996-12-10. PMID:8769400. |
acromegaly mainly associated with the presence of a growth hormone (gh)-secreting pituitary tumor causes considerable morbidity and carries a risk of premature mortality. |
1996-12-10 |
2023-08-12 |
Not clear |
| T P Ip, F L Chan, A W Kung, K S La. Giant growth-hormone secreting pituitary tumour with extracranial extension. Australasian radiology. vol 40. issue 1. 1996-12-10. PMID:8838899. |
serum growth hormone (gh) was 52.6 mu/l basally and remained elevated after oral glucose, confirming the diagnosis of acromegaly. |
1996-12-10 |
2023-08-12 |
Not clear |
| D Heuschmann, O Butenandt, M Voge. Left ventricular volume and mass in children on growth hormone therapy compared with untreated children. European journal of pediatrics. vol 155. issue 2. 1996-12-04. PMID:8775217. |
an excess of gh as in acromegaly, causes various problems within the circulatory system including cardiac hypertrophy. |
1996-12-04 |
2023-08-12 |
Not clear |
| H Ohtsuka, I Komiya, T Aizawa, T Yamad. Hypertension in acromegaly: hereditary hypertensive factor produces hypertension by enhancing IGF-I production. Endocrine journal. vol 42. issue 6. 1996-11-14. PMID:8822320. |
the above results suggest that the genetic factor produces hypertension in acromegaly by two ways, by increasing na and enhancing igf-i production by gh. |
1996-11-14 |
2023-08-12 |
Not clear |
| R Ochoa, E Fonseca, M Mercado, R E Galván, M Hernández, A Zárat. The magnitude of growth hormone elevation is related with the proportion of monomeric form in acromegaly. Archives of medical research. vol 26 Spec No. 1996-10-24. PMID:8845645. |
sera from 11 patients with active acromegaly were subjected to gel chromatography on sephadex g-100 column and fractions were collected for ria to measure gh. |
1996-10-24 |
2023-08-12 |
Not clear |
| E Ciccarelli, S Grottoli, P Razzore, L Gianotti, E Arvat, R Deghenghi, G Camanni, E Ghig. Hexarelin, a synthetic growth hormone releasing peptide, stimulates prolactin secretion in acromegalic but not in hyperprolactinaemic patients. Clinical endocrinology. vol 44. issue 1. 1996-09-11. PMID:8706295. |
we have therefore evaluated the effect of hexarelin on prl and gh secretion in patients with active acromegaly or pathological hyperprolactinaemia. |
1996-09-11 |
2023-08-12 |
Not clear |
| S J Padayatty, E J Perrins, P E Belchet. Octreotide treatment increases exercise capacity in patients with acromegaly. European journal of endocrinology. vol 134. issue 5. 1996-08-08. PMID:8664974. |
we conclude that the decrease in gh and igf-i following octreotide treatment of acromegaly is accompanied by decreased heart rate and increased exercise capacity despite an unchanged ejection fraction. |
1996-08-08 |
2023-08-12 |
Not clear |
| T Ishizuka, H Morita, T Mune, H Daidoh, J Hanafusa, M Yamamoto, T Shibata, K Yasud. Growth hormone secretion in human acromegalic pituitary adenomas: cyclic adenosine monophosphate and protein kinase C responses. Metabolism: clinical and experimental. vol 45. issue 2. 1996-04-18. PMID:8596491. |
we examined the effect of phorbol ester on growth hormone (gh)-releasing hormone (grh)-induced gh secretion and cyclic adenosine monophosphate (camp) production in three pituitary adenomas and thyrotropin-releasing hormone (trh)- and corticotropin-releasing hormone (crh)-induced redistribution of protein kinase c (pkc) from cytosol to membrane in a pituitary adenoma resected from patients with acromegaly. |
1996-04-18 |
2023-08-12 |
human |
| E E Müller, M Rolla, E Ghigo, D Belliti, E Arvat, A Andreoni, A Torsello, V Locatelli, F Camann. Involvement of brain catecholamines and acetylcholine in growth hormone hypersecretory states. Pathophysiological, diagnostic and therapeutic implications. Drugs. vol 50. issue 5. 1996-03-27. PMID:8586028. |
secretion of growth hormone (gh) is excessive in acromegaly, but also in a number of other pathological states such as anorexia nervosa, insulin-dependent diabetes mellitus (iddm), liver cirrhosis, depression, renal failure and gh-insensitivity syndrome. |
1996-03-27 |
2023-08-12 |
Not clear |
| E E Müller, M Rolla, E Ghigo, D Belliti, E Arvat, A Andreoni, A Torsello, V Locatelli, F Camann. Involvement of brain catecholamines and acetylcholine in growth hormone hypersecretory states. Pathophysiological, diagnostic and therapeutic implications. Drugs. vol 50. issue 5. 1996-03-27. PMID:8586028. |
abnormalities in the neuroendocrine control of gh secretion and/or a state of insensitivity to gh contribute to hypersecretion of gh in these states, with the possible exception of acromegaly, which appears to be a primary pituitary disease. |
1996-03-27 |
2023-08-12 |
Not clear |
| E E Müller, M Rolla, E Ghigo, D Belliti, E Arvat, A Andreoni, A Torsello, V Locatelli, F Camann. Involvement of brain catecholamines and acetylcholine in growth hormone hypersecretory states. Pathophysiological, diagnostic and therapeutic implications. Drugs. vol 50. issue 5. 1996-03-27. PMID:8586028. |
this review discusses the involvement of brain catecholamines and acetylcholine in gh hypersecretory states, including anorexia nervosa, acromegaly, iddm, liver cirrhosis, depression, renal failure and gh insensitivity syndrome, with a view to providing a fuller understanding of their pathophysiology and, whenever possible, diagnostic and therapeutic implications. |
1996-03-27 |
2023-08-12 |
Not clear |
| E Wolf, R Wanke, E Schenck, W Hermanns, G Bre. Effects of growth hormone overproduction on grip strength of transgenic mice. European journal of endocrinology. vol 133. issue 6. 1996-02-22. PMID:8548060. |
on the other hand, chronic hypersecretion of gh in active acromegaly may result in outwardly hypertrophied but functionally weaker muscles. |
1996-02-22 |
2023-08-12 |
mouse |
| A K Fløgstad, J Halse, T Haldorsen, I Lancranjan, P Marbach, C Bruns, J Jervel. Sandostatin LAR in acromegalic patients: a dose-range study. The Journal of clinical endocrinology and metabolism. vol 80. issue 12. 1996-01-31. PMID:8530606. |
we have investigated the efficacy and tolerability of sandostatin lar given as a single dose im to patients with active acromegaly who showed good gh suppression during a 2- to 4-week pretreatment period with octreotide given sc. |
1996-01-31 |
2023-08-12 |
Not clear |
| M Semer, A C Faria, M Nery, L R Salgado, M Knoepfelmacher, B L Wajchenberg, B Liberma. Growth hormone pulsatility in active and cured acromegalic subjects. The Journal of clinical endocrinology and metabolism. vol 80. issue 12. 1996-01-31. PMID:8530632. |
we studied gh secretion by cluster analysis, collecting samples every 20 min for 24 h in 44 subjects: 11 patients with active acromegaly; 16 "cured" acromegalics, and 17 normal subjects. |
1996-01-31 |
2023-08-12 |
human |
| M Semer, A C Faria, M Nery, L R Salgado, M Knoepfelmacher, B L Wajchenberg, B Liberma. Growth hormone pulsatility in active and cured acromegalic subjects. The Journal of clinical endocrinology and metabolism. vol 80. issue 12. 1996-01-31. PMID:8530632. |
the purpose of this study was to compare gh secretion between patients with active acromegaly and "cured" patients and between "cured" acromegalic patients and normal controls. |
1996-01-31 |
2023-08-12 |
human |
| N Tsukamoto, T Nagaya, A Kuwayama, K Takano, K Shizume, K Sugita, H Se. Octreotide treatment results in the inhibition of GH gene expression in the adenoma of the patients with acromegaly. Endocrine journal. vol 41. issue 4. 1996-01-29. PMID:8528360. |
octreotide treatment results in the inhibition of gh gene expression in the adenoma of the patients with acromegaly. |
1996-01-29 |
2023-08-12 |
human |
| C M Cuttica, P Sessarego, S Valenti, M R Falivene, M Giusti, G Giordan. Sumatriptan does not stimulate PRL and GH secretion in acromegaly. Minerva endocrinologica. vol 20. issue 2. 1996-01-26. PMID:8531896. |
sumatriptan does not stimulate prl and gh secretion in acromegaly. |
1996-01-26 |
2023-08-12 |
Not clear |
| C M Cuttica, P Sessarego, S Valenti, M R Falivene, M Giusti, G Giordan. Sumatriptan does not stimulate PRL and GH secretion in acromegaly. Minerva endocrinologica. vol 20. issue 2. 1996-01-26. PMID:8531896. |
we studied the effects of sumatriptan, a new 5-ht1d receptor agonist, on prl and gh secretion in active acromegaly. |
1996-01-26 |
2023-08-12 |
Not clear |
| P M Stewart, K F Kane, S E Stewart, I Lancranjan, M C Sheppar. Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly. The Journal of clinical endocrinology and metabolism. vol 80. issue 11. 1995-12-28. PMID:7593436. |
octreotide (sandostatin) is a synthetic analog of somatostatin, an endogenous gh inhibitory peptide that has been used as an adjunct to surgery and radiotherapy in the treatment of acromegaly. |
1995-12-28 |
2023-08-12 |
Not clear |